<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VANCOMYCIN HYDROCHLORIDE- vancomycin hydrochlorideÂ injection, powder, lyophilized, for solutionÂ </strong><br>Hospira, Inc.<br></p></div>
<h1>Vancomycin<br>
Hydrochloride for Injection, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a4856487-f508-4a63-b595-c6f88eedcde0"></a><a name="section-1"></a><p></p>
<h1></h1>
<table><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">PHARMACY BULK PACKAGEÂ  â€“ NOT FOR DIRECT INFUSION</td></tr></tbody></table>
<p class="First">Rx only</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="e199f826-d977-4c87-b16e-6c0713af6604"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Vancomycin Hydrochloride for Injection, USP, intravenous, is a chromatographically purified tricyclic glycopeptide antibiotic derived from <span class="Italics"><span class="Emphasis">Amycolatopsis orientalis</span></span> (formerly <span class="Italics"><span class="Emphasis">Nocardia orientalis</span></span>) and has the molecular formula C<span class="Sub">66</span>H<span class="Sub">75</span>Cl<span class="Sub">2</span>N<span class="Sub">9</span>O<span class="Sub">24</span> â€¢ HCl. The molecular weight is 1485.74; 500 mg of the base is equivalent to 0.34 mmol, 750 mg of the base is equivalent to 0.51 mmol, and 1 g of the base is equivalent to 0.67 mmol.</p>
<p>Vancomycin Hydrochloride has the following structural formula:</p>
<p><img alt="Vancomycin HCl structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b01aaa02-8f1d-4b57-96a5-337503428af1&amp;name=vancomycin-hcl-for-inj-usp-novation-figure-1-6509-sf.jpg"></p>
<p>The pharmacy bulk package contains sterile vancomycin hydrochloride equivalent to 5 grams vancomycin activity. Vancomycin Hydrochloride is a white to tan lyophilized powder. May contain hydrochloric acid and/or sodium hydroxide for pH adjustment. When reconstituted with Sterile Water for Injection, USP, it forms a clear, light to dark tan solution with a pH of 4.0 (2.5 to 4.5). This product is oxygen sensitive.</p>
<p>The vancomycin hydrochloride pharmacy bulk package is a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture service and restricted to the preparation of admixtures for intravenous infusion. <span class="Bold"><span class="Emphasis">AFTER RECONSTITUTION</span></span><span class="Bold"><span class="Emphasis"> FURTHER DILUTION IS REQUIRED BEFORE USE</span></span> (see <span class="Bold"><span class="Emphasis"><a href="#f7112995-d715-4944-98a3-dd566a37019c">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ecb84160-a47f-4fc9-bd67-412346ca8fc6"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Vancomycin is poorly absorbed after oral administration; it is given intravenously for therapy of systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Intramuscular injection is painful.</p>
<p>Vancomycin Hydrochloride for Injection, USP is administered intravenously for therapy of systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>In subjects with normal kidney function, multiple intravenous dosing of 1 g of vancomycin (15Â mg/kg) infused over 60 minutes produces mean plasma concentrations of approximately 63Â mcg/mL immediately after the completion of infusion, mean plasma concentrations of approximately 23 mcg/mL two hours after infusion, and mean plasma concentrations of approximately 8 mcg/mL eleven hours after the end of the infusion. Multiple dosing of 500 mg infused over 30 minutes produces mean plasma concentrations of about 49 mcg/mL at the completion of infusion, mean plasma concentrations of about 19 mcg/mL two hours after infusion, and mean plasma concentrations of about 10 mcg/mL six hours after infusion. The plasma concentrations during multiple dosing are similar to those after a single dose. </p>
<p>The mean elimination half-life of vancomycin from plasma is 4 to 6 hours in subjects with normal renal function. In the first 24 hours, about 75% of an administered dose of vancomycin is excreted in urine by glomerular filtration. Mean plasma clearance is about 0.058 L/kg/hr, and mean renal clearance is about 0.048 L/kg/hr. Renal dysfunction slows excretion of vancomycin. In anephric patients, the average half-life of elimination is 7.5 days. The distribution coefficient is from 0.3 to 0.43 L/kg. There is no apparent metabolism of the drug. About 60% of an intraperitoneal dose of vancomycin administered during peritoneal dialysis is absorbed systemically in six hours. Serum concentrations of about 10Â mcg/mL are achieved by intraperitoneal injection of 30 mg/kg of vancomycin. </p>
<p>However, the safety and efficacy of the intraperitoneal use of vancomycin has not been established in adequate and well-controlled trials (see <span class="Bold"><span class="Emphasis"><a href="#aa9c5765-0ea6-4afb-a422-0fe9a599de67">PRECAUTIONS</a></span></span>). </p>
<p>Total systemic and renal clearance of vancomycin may be reduced in the elderly. </p>
<p>Vancomycin is approximately 55% serum protein bound as measured by ultrafiltration at vancomycin serum concentrations of 10 to 100 mcg/mL. After I.V. administration of vancomycin hydrochloride, inhibitory concentrations are present in pleural, pericardial, ascitic, and synovial fluids; in urine; in peritoneal dialysis fluid; and in atrial appendage tissue. Vancomycin hydrochloride does not readily diffuse across normal meninges into the spinal fluid; but, when the meninges are inflamed, penetration into the spinal fluid occurs.</p>
<p><span class="Bold"><span class="Emphasis">Microbiology</span></span></p>
<p>The bactericidal action of vancomycin results primarily from inhibition of cell-wall biosynthesis. In addition, vancomycin alters bacterial-cell-membrane permeability and RNA synthesis. There is no cross-resistance between vancomycin and other antibiotics. Vancomycin is not active <span class="Italics"><span class="Emphasis">in vitro </span></span>against gram-negative bacilli, mycobacteria, or fungi.</p>
<p><span class="Bold"><span class="Emphasis">Synergy</span></span></p>
<p>The combination of vancomycin and an aminoglycoside acts synergistically <span class="Italics"><span class="Emphasis">in vitro </span></span>against many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="Emphasis">Staphylococcus aureus</span></span>, <span class="Italics"><span class="Emphasis">Streptococcus bovis</span></span>, enterococci, and the viridans group streptococci. </p>
<p>Vancomycin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics"><span class="Emphasis">in vitro </span></span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold"><span class="Emphasis"><a href="#d7e68564-602e-4566-b121-2865eb25216c">INDICATIONS AND USAGE</a>Â </span></span>section. </p>
<p><span class="Bold"><span class="Emphasis">Aerobic gram-positive microorganisms</span></span></p>
<p>Diphtheroids</p>
<p>Enterococci (e.g., <span class="Italics"><span class="Emphasis">Enterococcus faecalis</span></span>)</p>
<p>Staphylococci, including <span class="Italics"><span class="Emphasis">Staphylococcus aureus </span></span>and <span class="Italics"><span class="Emphasis">Staphylococcus epidermidis </span></span>(including heterogeneous methicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>) </p>
<p><span class="Italics"><span class="Emphasis">Streptococcus bovis</span></span></p>
<p>Viridans group streptococci</p>
<p>The following <span class="Italics"><span class="Emphasis">in vitro </span></span>data are available, <span class="Bold"><span class="Emphasis"><span class="Underline">but their clinical significance is unknown. </span></span></span>Vancomycin exhibits <span class="Italics"><span class="Emphasis">in vitro</span></span> MICâ€™s of 1 mcg/mL or less against most (â‰¥90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of streptococci listed below and MICâ€™s of 4 mcg/mL or less against most (â‰¥90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of other listed microorganisms; however, the safety and effectiveness of vancomycin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled clinical trials.</p>
<p><span class="Bold"><span class="Emphasis">Aerobic gram-positive microorganisms </span></span></p>
<p><span class="Italics"><span class="Emphasis">Listeria monocytogenes</span></span></p>
<p><span class="Italics"><span class="Emphasis">Streptococcus pyogenes</span></span></p>
<p><span class="Italics"><span class="Emphasis">Streptococcus pneumoniae </span></span>(including penicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><span class="Italics"><span class="Emphasis">Streptococcus agalactiae</span></span></p>
<p><span class="Bold"><span class="Emphasis">Anaerobic gram-positive microorganisms </span></span></p>
<p><span class="Italics"><span class="Emphasis">Actinomyces </span></span>species</p>
<p><span class="Italics"><span class="Emphasis">Lactobacillus </span></span>species</p>
<p><span class="Bold"><span class="Emphasis">Susceptibility Test Methods</span></span></p>
<p>When available, the clinical microbiology laboratory should provide the results of <span class="Italics"><span class="Emphasis">in vitro </span></span>susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.</p>
<p><span class="Bold"><span class="Emphasis">Dilution Techniques</span></span></p>
<p>Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MIC's). These MIC's provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MIC's should be determined using a standardized procedure. Standardized procedures are based on dilution method<span class="Sup">1,2</span> (broth, agar or microdilution) or equivalent using standardized inoculum and concentrations of vancomycin powder. The MIC values should be interpreted according to the criteria in Table 1.</p>
<p><span class="Bold"><span class="Emphasis">Diffusion Techniques</span></span></p>
<p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2,3</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 30 mcg of vancomycin to test the susceptibility of microorganisms to vancomycin. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for vancomycin.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with aÂ 30 mcg vancomycin disk should be interpreted according to the following criteria in Table 1.</p>
<table>
<caption><span>Table 1: Susceptibility Test Interpretive Criteria for Vancomycin</span></caption>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Pathogen</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom">
<p class="First"><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span></span></span></p>
<p><span class="Bold"><span class="Emphasis">(mcg/mL)</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom">
<p class="First"><span class="Bold"><span class="Emphasis">Disk Diffusion Diameters</span></span></p>
<p><span class="Bold"><span class="Emphasis">(mm)</span></span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold"><span class="Emphasis">Susceptible</span></span></p>
<p><span class="Bold"><span class="Emphasis">(S)</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold"><span class="Emphasis">Intermediate</span></span></p>
<p><span class="Bold"><span class="Emphasis">(I)</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold"><span class="Emphasis">Resistant</span></span></p>
<p><span class="Bold"><span class="Emphasis">(R)</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold"><span class="Emphasis">Susceptible</span></span></p>
<p><span class="Bold"><span class="Emphasis">(S)</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold"><span class="Emphasis">Intermediate</span></span></p>
<p><span class="Bold"><span class="Emphasis">(I)</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold"><span class="Emphasis">Resistant</span></span></p>
<p><span class="Bold"><span class="Emphasis">(R)</span></span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Italics"><span class="Emphasis">Enterococci </span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â‰¤4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">8 â€“ 16<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â‰¥32</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â‰¥17<span class="Sup">b</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">15 â€“ 16<span class="Sup">b</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â‰¤14<span class="Sup">b</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Italics"><span class="Emphasis">Staphylococcus aureus</span></span><span class="Sup">c,d</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â‰¤2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4 â€“ 8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â‰¥16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â€“â€“</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â€“â€“</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â€“â€“</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Coagulase-negative staphylococci<span class="Sup">c,e</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â‰¤4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">8 â€“ 16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â‰¥32</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â€“â€“</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â€“â€“</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â€“â€“</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Italics"><span class="Emphasis">Streptococci</span></span> spp. other than<span class="Italics"><span class="Emphasis"> S.Â pneumoniae</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â‰¤1<span class="Sup">f,g</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â€“â€“</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â€“â€“</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â‰¥17<span class="Sup">f,h</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â€“â€“</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">â€“â€“</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="7" valign="top">
<p class="First"><span class="Sup">a </span>Isolates with vancomycin MICs of 8 to 16 mcg/mL should be further screened for vancomycin resistance using standardized procedures.<span class="Sup">1,2</span></p>
<p><span class="Sup">b</span> Plates should be held for a full 24 hours and examined using transmitted light. Measure the diameter of the zones of complete inhibition (as judged by the unaided eye), including the diameter of the disk. The zone margin should be considered showing no obvious, visible growth that can be detected with the unaided eye. Ignore <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> growth of tiny colonies that can be detected only with a magnifying lens at the edge of the zone of inhibited growth. Any discernible growth within the zone of inhibition indicates vancomycin resistance. Organisms with intermediate zones should be tested by a standardized dilution method.<span class="Sup">1,2</span>Â </p>
<p><span class="Sup">c</span> Dilution testing should be performed to determine the susceptibility of all staphylococcal isolates. Disk diffusion testing is not reliable for testing vancomycin, as it does not differentiate vancomycin insusceptible isolates of <span class="Italics"><span class="Emphasis">S. aureus</span></span> from vancomycin-intermediate isolates, nor does it differentiate among vancomycin-susceptible, intermediate, and resistant isolates of coagulase-negative staphylococci.<span class="Sup">2</span></p>
<p><span class="Sup">d</span> Any <span class="Italics"><span class="Emphasis">S. aureus </span></span><span class="Underline"><span class="Emphasis">isolate for which the vancomycin MIC is â‰¥ 8 mcg/mL should be sent to a reference laboratory.</span></span><span class="Sup">2</span>Â </p>
<p><span class="Sup">e</span> Any coagulase-negative <span class="Italics"><span class="Emphasis">Staphylococcus </span></span><span class="Underline"><span class="Emphasis">isolate for which the vancomycin MIC is â‰¥ 32 mcg/mL should be sent to a reference laboratory.</span></span><span class="Sup">2</span></p>
<p><span class="Sup">f </span>The rare occurrence of resistant isolates precludes defining any results categories other than â€œSusceptibleâ€?. For isolates yielding results suggestive of a nonsusceptible category, organism identification and vancomycin susceptibility test results should be confirmed. If confirmed, isolates should be <span class="Underline"><span class="Emphasis">sent to a reference laboratory.</span></span><span class="Sup">2</span></p>
<p><span class="Sup">g </span>Interpretative criteria applicable only to tests performed by broth microdilution method using cation-adjusted Mueller-Hinton broth with 2 to 5% lysed horse blood.<span class="Sup">1,2</span></p>
<p><span class="Sup">h </span>Interpretative criteria applicable only to tests performed by disk diffusion method using Mueller-Hinton agar with 5% defibrinated sheep blood and incubated in 5% CO<span class="Sub">2</span><span class="Sup">3</span>.</p>
</td></tr>
</tbody>
</table>
<p>A report of â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of â€œIntermediateâ€? indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of â€œResistantâ€? indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
<p><span class="Bold"><span class="Emphasis">Quality Control</span></span></p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test. When tested against appropriate quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>, standard vancomycin powder should provide MIC values shown in Table 2. For the diffusion technique, the 30 mcg vancomycin disk should provide the following zone diameters in Table 2 with the quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>.</p>
<table width=" 98%">
<caption><span>Table 2. In Vitro Susceptibility Test Quality Control Ranges for Vancomycin</span></caption>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Organism (ATCC #)</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">MIC range (mcg/mL)</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Disk diffusion range (mm)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Italics"><span class="Emphasis">Enterococcus faecalis </span></span>(29212)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 â€“ 4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Not applicable</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Italics"><span class="Emphasis">Staphylococcus aureus</span></span> (29213)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5 â€“ 2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Not applicable</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Italics"><span class="Emphasis">Staphylococcus aureus</span></span> (25923)<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Not applicable</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">17 â€“ 21</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Italics"><span class="Emphasis">Streptococcus pneumoniae</span></span> (49619)<span class="Sup">b,c</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.12 â€“ 0.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20 â€“ 27</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="3" valign="top">
<p class="First"><span class="Sup">a</span> Quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> and interpretive criteria for testing vancomycin susceptibility of <span class="Italics"><span class="Emphasis">Enterococci</span></span> spp.</p>
<p><span class="Sup">b</span> Interpretative criteria applicable only to tests performed using cation-adjusted Mueller-Hinton broth with 2 to 5% lysed horse blood<span class="Sup">1</span>. Disk diffusion interpretive criteria applicable only to tests performed using Mueller-Hinton agar with 5% defibrinated sheep blood and incubated in 5% CO<span class="Sub">2</span>.</p>
<p><span class="Sup">c </span>Quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> and interpretive criteria for testing vancomycin susceptibility of <span class="Italics"><span class="Emphasis">Streptococci </span></span>spp. other than <span class="Italics"><span class="Emphasis">S. pneumoniae.</span></span></p>
</td></tr>
</tbody>
</table>
<p>Â </p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="d7e68564-602e-4566-b121-2865eb25216c"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Vancomycin hydrochloride is indicated for the treatment of serious or severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly.</p>
<p>Vancomycin hydrochloride is effective in the treatment of staphylococcal <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>. Itâ€™s effectiveness has been documented in other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to staphylococci, including <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, bone <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infections</span>, and skin and skin-structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. When <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infections</span> are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures.</p>
<p>Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> caused by <span class="Italics"><span class="Emphasis">S. viridans </span></span>or <span class="Italics"><span class="Emphasis">S. bovis</span></span>. For <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> caused by enterococci (e.g., <span class="Italics"><span class="Emphasis">E. faecalis</span></span>), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside.</p>
<p>Vancomycin hydrochloride has been reported to be effective for the treatment of diphtheroid <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>. Vancomycin hydrochloride has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> caused by <span class="Italics"><span class="Emphasis">S. epidermidis</span></span> or diphtheroids.</p>
<p>Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin hydrochloride.</p>
<p>The parenteral form of vancomycin hydrochloride may be administered orally for treatment of antibiotic-associated <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> produced by <span class="Italics"><span class="Emphasis">C. difficile </span></span>and for staphylococcal <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. <span class="Bold"><span class="Emphasis">Vancomycin hydrochloride is not effective by the oral route for other types of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</span></span></p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="bdbf0492-7881-454d-ab1f-40535cfd5e38"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Vancomycin Hydrochloride for Injection, USP is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to this antibiotic.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="d6972410-3f2f-4365-bebf-59fc344ef8b4"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Rapid bolus administration (e.g., over several minutes) may be associated with exaggerated <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and rarely <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. Vancomycin hydrochloride should be administered in a dilute solution over a period of not less than 60 minutes to avoid rapid-infusion-related reactions. Stopping the infusion usually results in a prompt cessation of these reactions. </p>
<p><span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> has occurred in patients receiving vancomycin hydrochloride. It may be transient or permanent. It has been reported mostly in patients who have been given excessive doses, who have an underlying <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, or who are receiving concomitant therapy with another ototoxic agent, such as an aminoglycoside. Vancomycin should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> because the risk of toxicity is appreciably increased by high, prolonged blood concentrations.</p>
<p>Dosage of vancomycin hydrochloride must be adjusted for patients with renal dysfunction (see <span class="Bold"><span class="Emphasis"><a href="#aa9c5765-0ea6-4afb-a422-0fe9a599de67">PRECAUTIONS</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#f7112995-d715-4944-98a3-dd566a37019c">DOSAGE AND ADMINISTRATION</a></span></span>). </p>
<p><span class="Italics"><span class="Emphasis">Clostridium difficile</span></span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including Vancomycin Hydrochloride for Injection, USP, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics"><span class="Emphasis">C. difficile.</span></span></p>
<p><span class="Italics"><span class="Emphasis">C. difficile </span></span>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="Emphasis">C. difficile </span></span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not direct against <span class="Italics"><span class="Emphasis">C. difficile</span></span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics"><span class="Emphasis">C. difficile,</span></span> and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="aa9c5765-0ea6-4afb-a422-0fe9a599de67"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="Bold"><span class="Emphasis">General</span></span></p>
<p>Clinically significant serum concentrations have been reported in some patients who have taken multiple oral doses of vancomycin for active <span class="Italics"><span class="Emphasis">C. difficile</span></span>-induced <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>.</p>
<p>Prolonged use of vancomycin may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during therapy, appropriate measures should be taken. In rare instances, there have been reports of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> due to <span class="Italics"><span class="Emphasis">C. difficile</span></span> developing in patients who receive intravenous vancomycin.</p>
<p>In order to minimize the risk of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> when treating patients with underlying renal dysfunction or patients receiving concomitant therapy with an aminoglycoside, serial monitoring of renal function should be performed and particular care should be taken in following appropriate dosing schedules (see <span class="Bold"><span class="Emphasis"><a href="#f7112995-d715-4944-98a3-dd566a37019c">DOSAGE AND ADMINISTRATION</a></span></span>). </p>
<p>Serial tests of auditory function may be helpful in order to minimize the risk of <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>. </p>
<p>Reversible <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> has been reported in patients receiving vancomycin hydrochloride (see <span class="Bold"><span class="Emphasis"><a href="#e7370ed3-1116-422b-9489-1f03bb6bfa0c">ADVERSE REACTIONS</a></span></span>). Patients who will undergo prolonged therapy with vancomycin hydrochloride or those who are receiving concomitant drugs which may cause <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have periodic monitoring of the leukocyte count. </p>
<p>Vancomycin hydrochloride is irritating to tissue and must be given by a secure intravenous route of administration. <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> occur with intramuscular injection or with inadvertent <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>. <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> may occur, the frequency and severity of which can be minimized by administering the drug slowly as a dilute solution (2.5 to 5 g/L) and by rotation of venous access sites.</p>
<p>There have been reports that the frequency of infusion-related events (including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, erythemia, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>) increases with the concomitant administration of anesthetic agents. Infusion-related events may be minimized by the administration of vancomycin hydrochloride as a 60-minute infusion prior to anesthetic induction.</p>
<p>The safety and efficacy of vancomycin administration by the intrathecal (intralumbar or intraventricular) route or by intraperitoneal route have not been established by adequate and well-controlled trials.</p>
<p>Reports have revealed that administration of Vancomycin Hydrochloride for Injection, USP by the intraperitoneal route during continuous ambulatory peritoneal dialysis (CAPD) has resulted in a syndrome of chemical <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>. To date, this syndrome has ranged from a cloudy dialysate alone to a cloudy dialysate accompanied by variable degrees of <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. This syndrome appears to be short-lived after discontinuation of intraperitoneal vancomycin.</p>
<p>Prescribing vancomycin in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p><span class="Bold"><span class="Emphasis">Information for Patients</span></span></p>
<p>Patients should be counseled that antibacterial drugs including vancomycin should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When vancomycin is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, the patient should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by vancomycin or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
<p><span class="Bold"><span class="Emphasis">Drug Interactions</span></span></p>
<p>Concomitant administration of vancomycin and anesthetic agents has been associated with <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and histamine-like <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> (see <span class="Bold"><span class="Emphasis">Pediatric Use </span></span>under<span class="Bold"><span class="Emphasis">Â <a href="#aa9c5765-0ea6-4afb-a422-0fe9a599de67">PRECAUTIONS</a></span></span>) and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> (see <span class="Bold"><span class="Emphasis"><a href="#e7370ed3-1116-422b-9489-1f03bb6bfa0c">ADVERSE REACTIONS</a></span></span>).</p>
<p>Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.</p>
<p><span class="Bold"><span class="Emphasis">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></span>Â </p>
<p>Although no long-term studies in animals have been performed to evaluate carcinogenic potential, no mutagenic potential of Vancomycin Hydrochloride for Injection, USP was found in standard laboratory tests. No definitive fertility studies have been performed.</p>
<p><span class="Bold"><span class="Emphasis">Pregnancy</span></span></p>
<p><span class="Bold"><span class="Emphasis">Teratogenic Effects</span></span></p>
<p><span class="Bold"><span class="Emphasis">Category C</span></span></p>
<p>Animal reproduction studies have not been conducted with Vancomycin hydrochloride. It is not known whether Vancomycin hydrochloride can affect reproduction capacity. In a controlled clinical study, the potential ototoxic and nephrotoxic effects of Vancomycin hydrochloride on infants were evaluated when the drug was administered to pregnant women for serious <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infections</span> complicating intravenous drug abuse. Vancomycin hydrochloride was found in cord blood. No <span class="product-label-link" type="condition" conceptid="374366" conceptname="Sensorineural hearing loss">sensorineural hearing loss</span> or <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> attributable to vancomycin was noted. One infant whose mother received vancomycin in the third trimester experienced <span class="product-label-link" type="condition" conceptid="377888" conceptname="Conductive hearing loss">conductive hearing loss</span> that was not attributed to the administration of vancomycin. Because the number of patients treated in this study was limited and vancomycin was administered only in the second and third trimesters, it is not known whether vancomycin causes fetal harm. Vancomycin hydrochloride should be given to a pregnant woman only if clearly needed.</p>
<p><span class="Bold"><span class="Emphasis">Nursing Mothers</span></span></p>
<p>Vancomycin is excreted in human milk. Caution should be exercised when vancomycin hydrochloride is administered to a nursing woman. Because of the potential for adverse events, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
<p><span class="Bold"><span class="Emphasis">Pediatric Use</span></span></p>
<p>In premature neonates and young infants, it may be appropriate to confirm desired vancomycin serum concentrations. Concomitant administration of vancomycin and anesthetic agents has been associated with <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and histamine-like <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> in pediatric patients (see <span class="Bold"><span class="Emphasis"><a href="#e7370ed3-1116-422b-9489-1f03bb6bfa0c">ADVERSE REACTIONS</a></span></span>).</p>
<p><span class="Bold"><span class="Emphasis">Geriatric Use</span></span></p>
<p>The natural decrement of glomerular filtration with increasing age may lead to elevated vancomycin serum concentrations if dosage is not adjusted. Vancomycin dosage schedules should be adjusted in elderly patients (see <span class="Bold"><span class="Emphasis"><a href="#f7112995-d715-4944-98a3-dd566a37019c">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="e7370ed3-1116-422b-9489-1f03bb6bfa0c"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold"><span class="Emphasis">Infusion-Related Events</span></span></p>
<p>During or soon after rapid infusion of vancomycin hydrochloride, patients may develop <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (see <span class="Bold"><span class="Emphasis"><a href="#ee89160a-70c3-4bdd-aa83-f15b7dfb848f">ANIMAL PHARMACOLOGY</a></span></span>), <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. Rapid infusion may also cause <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> of the upper body (â€œred neckâ€?) or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span> of the chest and back. These reactions usually resolve within 20 minutes but may persist for several hours. Such events are infrequent if vancomycin hydrochloride is given by a slow infusion over 60 minutes. In studies of normal volunteers, infusion-related events did not occur when vancomycin hydrochloride was administered at a rate of 10 mg/min or less.</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span></span></span></p>
<p><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span>, principally manifested by increased serum creatinine or BUN concentrations, especially in patients given large doses of vancomycin, has been reported. Rare cases of interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> have been reported. Most of these have occurred in patients who were given aminoglycosides concomitantly or who had preexisting <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">kidney dysfunction</span>. When vancomycin hydrochloride was discontinued, <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> resolved in most patients.</p>
<p><span class="Bold"><span class="Emphasis">Gastrointestinal</span></span></p>
<p>Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibiotic treatment (see <span class="Bold"><span class="Emphasis"><a href="#d6972410-3f2f-4365-bebf-59fc344ef8b4">WARNINGS</a></span></span>).</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span></span></span></p>
<p>A few dozen cases of <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> associated with vancomycin hydrochloride have been reported. Most of these patients had <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">kidney dysfunction</span> or a preexisting <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, or were receiving concomitant treatment with an ototoxic drug. <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> have been reported rarely.</p>
<p><span class="Bold"><span class="Emphasis">Hematopoietic</span></span></p>
<p>Reversible <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, usually starting one week or more after onset of therapy with vancomycin hydrochloride or after a total dosage of more than 25 g, has been reported for several dozen patients. <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> appears to be promptly reversible when vancomycin hydrochloride is discontinued. <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> has rarely been reported.</p>
<p>Although a causal relationship has not been established, reversible <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> (granulocytes &lt;500/mm<span class="Sup">3</span>) has been reported rarely.</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span></span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> at the injection site has been reported. </p>
<p><span class="Bold"><span class="Emphasis">Miscellaneous</span></span></p>
<p>Infrequently, patients have been reported to have had <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> (including <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>), <span class="product-label-link" type="condition" conceptid="4317262" conceptname="Linear IgA dermatosis">linear IgA bullous dermatosis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and rare cases of <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> in association with the administration of vancomycin.</p>
<p>Chemical <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> has been reported following intraperitoneal administration of vancomycin (see <span class="Bold"><span class="Emphasis"><a href="#aa9c5765-0ea6-4afb-a422-0fe9a599de67">PRECAUTIONS</a></span></span>).</p>
<p><span class="Bold"><span class="Emphasis">Post Marketing Reports</span></span></p>
<p>The following adverse reactions have been identified during post-approval use of vancomycin. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to the drug exposure.</p>
<p>Skin and Subcutaneous Tissue Disorders</p>
<p><span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">Drug Rash</span> with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS)</p>
<p>To report SUSPECTED ADVERSE EVENTS, contact FDA at 1-800-FDA-1088 or www.fda.gov.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="e64d74ed-3039-42bb-99ef-071eb2914179"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Supportive care is advised, with maintenance of glomerular filtration. Vancomycin is poorly removed by dialysis. Hemofiltration and hemoperfusion with polysulfone resin have been reported to result in increased vancomycin clearance.</p>
<p>The median lethal intravenous dose is 319 mg/kg in rats and 400 mg/kg in mice. </p>
<p>To obtain up-to-date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the <span class="Italics"><span class="Emphasis">Physiciansâ€™ Desk Reference (PDR)</span></span>. In managing overdosage, consider the possibility of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span>, interaction among drugs, and unusual drug kinetics in your patient. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="f7112995-d715-4944-98a3-dd566a37019c"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">An infusion rate of 10 mg/min or less is associated with fewer infusion-related events (see <span class="Bold"><span class="Emphasis"><a href="#e7370ed3-1116-422b-9489-1f03bb6bfa0c">ADVERSE REACTIONS</a></span></span>). Infusion-related events are related to both concentration and rate of administration of vancomycin. Concentrations of no more than 5 mg/mL and rates of no more than 10 mg/min are recommended in adults (see also age-specific recommendations). </p>
<p>In selected patients in need of fluid restriction, a concentration up to 10 mg/mL may be used; use of such higher concentrations may increase the risk of infusion-related events. Infusion-related events may occur, however, at any rate or concentration.</p>
<p><span class="Bold"><span class="Emphasis">Patients with Normal Renal Function</span></span></p>
<p><span class="Bold"><span class="Emphasis">Adults</span></span></p>
<p>The usual intravenous daily dose is 2 g divided either as 500 mg every six hours or 1 g every 12 hours. Each dose should be administered at no more than 10 mg/min, or over a period of at least 60 minutes, whichever is longer. Other patient factors, such as age or <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, may call for modification of the usual daily dose.</p>
<p><span class="Bold"><span class="Emphasis">Pediatric Patients</span></span></p>
<p>The usual intravenous dosage of vancomycin is 10 mg/kg per dose given every six hours. Each dose should be administered over a period of at least 60 minutes. Close monitoring of serum concentrations of vancomycin is recommended in these patients.</p>
<p><span class="Bold"><span class="Emphasis">Neonates</span></span></p>
<p>In pediatric patients up to the age of 1 month, the total daily intravenous dosage may be lower. In neonates, an initial dose of 15 mg/kg is suggested, followed by 10 mg/kg every 12 hours for neonates in the first week of life and every eight hours thereafter up to the age of one month. Each dose should be administered over 60 minutes. In premature infants, vancomycin clearance decreases as postconceptional age decreases. Therefore, longer dosing intervals may be necessary in premature infants. Close monitoring of serum concentrations of vancomycin is recommended in these patients.</p>
<p><span class="Bold"><span class="Emphasis">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span> and Elderly Patients</span></span></p>
<p>Dosage adjustment must be made in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. In premature infants and in the elderly, greater dosage reductions than expected may be necessary because of decreased renal function. Measurement of vancomycin serum concentrations can be helpful in optimizing therapy, especially in seriously ill patients with changing renal function. Vancomycin serum concentrations can be determined by use of microbiologic assay, radioimmunoassay, fluorescence polarization immunoassay, fluorescence immunoassay, or high-pressure liquid chromatography.</p>
<p>If creatinine clearance can be measured or estimated accurately, the dosage for most patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> can be calculated using the following table. The dosage of vancomycin hydrochloride per day in mg is about 15 times the glomerular filtration rate in mL/min: </p>
<table>
<caption><span>DOSAGE TABLE FOR VANCOMYCIN IN PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">IMPAIRED RENAL FUNCTION</span> (Adapted from Moellering et al)<span class="Sup">4</span></span></caption>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold"><span class="Emphasis">Creatinine Clearance</span></span></p>
<p><span class="Bold"><span class="Emphasis">mL/min</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">Vancomycin Dose</span></span></p>
<p><span class="Bold"><span class="Emphasis">mg/24 h</span></span></p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">100</p>
<p>90</p>
<p>80</p>
<p>70</p>
<p>60</p>
<p>50</p>
<p>40</p>
<p>30</p>
<p>20</p>
<p>10</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">1,545</p>
<p>1,390</p>
<p>1,235</p>
<p>1,080</p>
<p>925</p>
<p>770</p>
<p>620</p>
<p>465</p>
<p>310</p>
<p>155</p>
</td>
</tr>
</tbody>
</table>
<p>The initial dose should be no less than 15 mg/kg, even in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
<p>The table is not valid for functionally anephric patients. For such patients, an initial dose of 15 mg/kg of body weight should be given to achieve prompt therapeutic serum concentrations. The dose required to maintain stable concentrations is 1.9 mg/kg/24 h. In patients with marked <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, it may be more convenient to give maintenance doses of 250 to 1000 mg once every several days rather than administering the drug on a daily basis. In <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, a dose of 1000 mg every 7 to 10 days has been recommended.</p>
<p>When only serum creatinine concentration is known, the following formula (based on sex, weight, and age of the patient) may be used to calculate creatinine clearance. Calculated creatinine clearances (mL/min) are only estimates. The creatinine clearance should be measured promptly.</p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"><p class="First">Men:</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Underline"><span class="Emphasis">Weight (kg) x (140 - age in years)</span></span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">72 x serum creatinine concentration (mg/dL)</p></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Women:</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">0.85 x above value</p></td>
</tr>
</tbody></table>
<p>The serum creatinine must represent a steady state of renal function. Otherwise, the estimated value for creatinine clearance is not valid. Such a calculated clearance is an overestimate of actual clearance in patients with conditions: (1) characterized by decreasing renal function, such as <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>; (2) in which a normal relationship between <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span> and total body weight is not present, such as in obese patients or those with liver disease, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, or <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>; and (3) accompanied by debilitation, <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span>, or inactivity.</p>
<p>The safety and efficacy of vancomycin administration by the intrathecal (intralumbar or intraventricular) routes have not been established.</p>
<p>Intermittent infusion is the recommended method of administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a9fb140f-aef5-4c3d-b16b-8bd0913624f2"></a><a name="section-11"></a><p></p>
<h1>PREPARATION AND STABILITY</h1>
<p class="First"><span class="Bold"><span class="Emphasis">DIRECTIONS FOR PROPER USE OF PHARMACY BULK PACKAGEÂ â”€Â NOT FOR DIRECT INFUSION.</span></span> The pharmacy bulk package is for use in the Hospital Pharmacy Admixture Service only in a suitable work area such as a laminar flow hood. Using aseptic technique, the closure may be penetrated only one time after reconstitution using a suitable sterile transfer device or dispensing set, which allows measured dispensing of the contents. Use of a syringe and needle is not recommended as it may cause leakage. After entry use entire contents of bottle promptly. The entire contents of the bottle should be dispensed within <span class="Bold"><span class="Emphasis">4</span></span>Â <span class="Bold"><span class="Emphasis">HOURS</span></span> after entry. This time limit should begin with the introduction of solvent into the Pharmacy Bulk Package.</p>
<p>At the time of use, reconstitute by adding 100 mL of Sterile Water for Injection to the bottle containing 5 grams of dry, sterile vancomycin powder. <span class="Bold"><span class="Emphasis">AFTER RECONSTITUTION FURTHER DILUTION IS REQUIRED BEFORE USE</span></span>. </p>
<p>Reconstituted solutions with 10 mL containing 500 mg of vancomycin must be diluted with at least 100Â mL of diluent. Reconstituted solutions with 20 mL containing 1 g must be diluted with at least 200Â mL of diluent. The desired dose diluted in this manner should be administered by intermittent intravenous infusion over a period of at least 60 minutes. </p>
<p><span class="Bold"><span class="Emphasis">Compatibility with Other Drugs and Intravenous Fluids</span></span></p>
<p>The following diluents are physically and chemically compatible (with 5 mg/mL vancomycin, present as the HCl):</p>
<p>5% Dextrose Injection, USP</p>
<p>5% Dextrose and 0.9% Sodium Chloride Injection, USP</p>
<p>Lactated Ringerâ€™s Injection, USP</p>
<p>5% Dextrose and Lactated Ringerâ€™s Injection</p>
<p>Normosol<span class="Sup">Â®</span>-M and 5% Dextrose</p>
<p>0.9% Sodium Chloride Injection, USP</p>
<p>ISOLYTE<span class="Sup">Â®</span> E</p>
<p>Good professional practice suggests that administration of compounded admixtures should be administered as soon after preparation as is feasible. </p>
<p>Vancomycin solution has a low pH and may cause physical instability when it is mixed with other compounds.</p>
<p>Mixtures of solutions of vancomycin and beta-lactam antibiotics have been shown to be physically incompatible. The likelihood of precipitation increases with higher concentrations of vancomycin. It is recommended to adequately flush the intravenous lines between the administration of these antibiotics. It is also recommended to dilute solutions of vancomycin to 5 mg/mL or less.</p>
<p>Although intravitreal injection is not an approved route of administration for vancomycin, precipitation has been reported after intravitreal injection of vancomycin and ceftazidime for <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span> using different syringes and needles. The precipitates dissolved gradually, with complete clearing of the vitreous cavity over two months and with improvement of visual acuity.</p>
<p>Prior to administration, parenteral drug products should be visually inspected for particulate matter and discoloration prior to administration, whenever solution or container permits.</p>
<p><span class="Bold"><span class="Emphasis">For Oral Administration</span></span></p>
<p>Oral vancomycin is used in treating antibiotic-associated <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> caused by <span class="Italics"><span class="Emphasis">C. difficile </span></span>and for staphylococcal <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>. Vancomycin is not effective by the oral route for other types of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. The usual adult total daily dosage is 500 mg to 2 g given in 3 or 4 divided doses for 7 to 10 days. The total daily dosage in pediatric patients is 40 mg/kg of body weight in 3 or 4 divided doses for 7Â to 10 days. The total daily dosage should not exceed 2 g. The appropriate dose may be diluted in 1 oz. of water and given to the patient to drink. The diluted solution Â may be administered via nasogastric tube. Common flavoring syrups may be added to the solution to improve the taste for oral administration.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ad6b95ea-805c-42de-8deb-5b6313758f2f"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Vancomycin Hydrochloride for Injection, USP is supplied as a sterile powder in a Pharmacy Bulk Package bottle equivalent to 5 grams vancomycin. NDC No. 0409-6509-49.</p>
<p>Prior to reconstitution, store at 20 to 25Â°C (68 to 77Â°F). [See USP Controlled Room Temperature.]</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="ee89160a-70c3-4bdd-aa83-f15b7dfb848f"></a><a name="section-13"></a><p></p>
<h1>ANIMAL PHARMACOLOGY</h1>
<p class="First">In animal studies, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> occurred in dogs receiving an intravenous infusion of vancomycin, 25 mg/kg, at a concentration of 25 mg/mL and an infusion rate of 13.3 mL/min.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="d9530ac5-016d-41ec-abb2-d2f866e4cbc2"></a><a name="section-14"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard â€“ 8th ed., CLSI document M07-A8. Clinical and Laboratory Standards Institute. Wayne, PA. January, 2009. </li>
<li>Performance Standards for Antimicrobial Susceptibility Testing; 21st Informational Supplement, CLSI document M100-S21. Clinical and Laboratory Standards Institute. Wayne, PA. January, 2011. </li>
<li>Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard â€“ 10th ed., CLSI document M02-A10. Clinical and Laboratory Standards Institute. Wayne, PA. January, 2009. </li>
<li>Moellering RC, Krogstad DJ, Greenblatt DJ: Vancomycin therapy in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>: A nomogram for dosage. <span class="Italics"><span class="Emphasis">Ann Inter Med </span></span>1981;94:343.</li>
</ol>
<p class="First">Revised: 2/2014</p>
<p>ISOLYTE<span class="Sup">Â®</span> E is a registered trademark of B. Braun</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  EN-3440</p>
<p>Manufactured and distributed by Hospira, Inc., Lake Forest, IL 60045 USA</p>
<p>NOVAPLUS<span class="Sup">Â®</span> is a registered trademark of Novation, LLC.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="b3d192e2-54fc-46f2-a02c-431980b6967d"></a><a name="section-15"></a><p></p>
<h1>CA-2718</h1>
<div class="Figure"><img alt="Carton NDC 0409-6509-49" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b01aaa02-8f1d-4b57-96a5-337503428af1&amp;name=vancomycin-hcl-for-inj-usp-novation-figure-2-jCA-2718.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VANCOMYCIN HYDROCHLORIDEÂ 		
					</strong><br><span class="contentTableReg">vancomycin hydrochloride injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0409-6509</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VANCOMYCIN HYDROCHLORIDE</strong> (VANCOMYCIN) </td>
<td class="formItem">VANCOMYCIN</td>
<td class="formItem">500Â mg Â inÂ 10Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0409-6509-49</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 VIAL, PHARMACY BULK PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA063076</td>
<td class="formItem">12/21/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Hospira, Inc.
							(141588017)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7f8fbb70-0b6e-4b80-a172-15c547407448</div>
<div>Set id: b01aaa02-8f1d-4b57-96a5-337503428af1</div>
<div>Version: 1</div>
<div>Effective Time: 20140429</div>
</div>
</div>Â <div class="DistributorName">Hospira, Inc.</div></p>
</body></html>
